WHAT IS CLAIMED:

1. An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising:

(a) a heavy chain CDR1 amino acid sequence set forth in ~~Table 1 or~~ SEQ ID NOs: 13, 19 and 25, or a variant thereof in which one or two amino acids have been changed;

(b) a heavy chain CDR2 amino acid sequence set forth in ~~Table 1 or~~ SEQ ID NOs: 14, 20 and 26 that is from the same heavy chain variable region as (a), or a variant thereof in which one or two amino acids have been changed; ~~and~~

(c) a heavy chain CDR3 amino acid sequence set forth in ~~Table 1 or~~ SEQ ID NOs: 15, 21 and 27 that is from the same heavy chain variable region as (a), or a variant thereof in which one or two amino acids have been changed;

(d) a light chain CDR1 amino acid sequence set forth in SEQ ID NO: 16, 22 and 28, or a variant thereof in which one or two amino acids have been changed;

(e) a light chain CDR2 amino acid sequence set forth in SEQ ID NO: 17, 23 and 29, or a variant thereof in which one or two amino acids have been changed; and

(f) a light chain CDR3 amino acid sequence set forth in SEQ ID NO: 18, 24 and 30, or a variant thereof in which one or two amino acids have been changed.

~~2. An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising:~~

~~(a) a heavy chain CDR1 amino acid sequence set forth in Table 1 or SEQ ID NOs: 13, 19 and 25, or a variant thereof having at least 70% identity thereto;~~

~~(b) a heavy chain CDR2 amino acid sequence set forth in Table 1 or SEQ ID NOs: 14, 20 and 26 that is from the same heavy chain variable region as (a), or a variant thereof having at least 70% identity thereto; and~~

~~(c) a heavy chain CDR3 amino acid sequence set forth in Table 1 or SEQ ID NOs: 15, 21 and 27 that is from the same heavy chain variable region as (a), or a variant thereof having at least 70% identity thereto.~~

~~3. An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising:~~

~~(a) a heavy chain CDR1 amino acid sequence set forth in Table 1 or SEQ ID NOs: 13, 19 and 25, or a variant thereof having at least 70% identity thereto;~~

~~(b) an independently selected heavy chain CDR2 amino acid sequence set forth in Table 1 or SEQ ID NOs: 14, 20 and 26, or a variant thereof having at least 70% identity thereto; and~~

~~(c) an independently selected heavy chain CDR3 amino acid sequence set forth in Table 1 or SEQ ID NOs: 15, 21 and 27, or a variant thereof having at least 70% identity thereto.~~

~~4. The antibody of any one of claims 1 to 3, wherein at least two of the heavy chain CDR1, CDR2 or CDR3 amino acid sequences are set forth in Table 1 or SEQ ID NOs: 13-15, 19-21 and 25-27.~~

~~5. The antibody of any one of claims 1 to 3, wherein three of the heavy chain CDR1, CDR2 and CDR3 amino acid sequences are set forth in Table 1 or SEQ ID NOs: 13-15, 19-21 and 25-27.~~

~~6. The antibody of any one of claims 1 to 5, that comprises an amino acid sequence at least 85% identical to a heavy chain variable region amino acid sequence set forth in Table 1 or SEQ ID NOs: 2, 6 and 10.~~

~~7~~2. The antibody of ~~any one of~~ claim~~s~~ 1 ~~to 6~~, that comprises an amino acid sequence at least 95% identical to a heavy chain variable region amino acid sequence set forth in ~~Table 1 or~~ SEQ ID NOs: 2, 6 and 10.

~~8. The antibody of any one of claims 1 to 3, comprising a polypeptide sequence having an amino acid sequence at least 70% identical over all three HCDRs in a heavy chain variable region, the amino acid sequences of HCDR1, HCDR2 and HCDR3 set forth in SEQ ID NOs: 13-15, 19-21 and 25-27.~~

~~9~~3. The antibody of ~~any one of~~ claim~~s~~ 1 ~~to~~or ~~8~~2, in which one or more heavy chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.

~~10. The antibody of any one of claims 1 to 9, that further comprises any one of the light chain CDR amino acid sequences set forth in Table 1 or SEQ ID NOs: 16-18, 22-24 and 28-30.~~

~~11. The antibody of any one of claims 1 to 10, that comprises at least two of the light chain CDR amino acid sequences set forth in Table 1 or SEQ ID NOs: 16-18, 22-24 and 28-30.~~

~~12. The antibody of any one of claims 1 to 11, that comprises at least three of the light chain CDR amino acid sequences set forth in Table 1 or SEQ ID NOs: 16-18, 22-24 and 28-30.~~

~~13. The antibody of any one of claims 1 to 9 that comprises:~~

~~(a) a light chain CDR1 amino acid sequence set forth in Table 1 or SEQ ID NOs: 16, 22 and 28, or a variant thereof in which one or two amino acids have been changed;~~

~~(b) a light chain CDR2 amino acid sequence set forth in Table 1 or SEQ ID NOs: 17, 23 and 29 that is from the same light chain variable region as (a), or a variant thereof in which one or two amino acids have been changed; and~~

~~(c) a light chain CDR3 amino acid sequence set forth in Table 1 or SEQ ID NOs: 18, 24 and 30 that is from the same light chain variable region as (a), or a variant thereof in which one or two amino acids have been changed.~~

~~14. The antibody of any one of claims 1 to 9 that comprises:~~

~~(a) a light chain CDR1 amino acid sequence set forth in Table 1 or SEQ ID NOs: 16, 22 and 28, or a variant thereof in which one or two amino acids have been changed;~~

~~(b) an independently selected light chain CDR2 amino acid sequence set forth in Table 1 or SEQ ID NOs: 17, 23 and 29, or a variant thereof in which one or two amino acids have been changed; and~~

~~(c) an independently selected light chain CDR3 amino acid sequence set forth in Table 1 or SEQ ID NOs: 18, 24 and 30, or a variant thereof in which one or two amino acids have been changed.~~

~~15. The antibody of claim 13 or 14, wherein at least two of the light chain CDR1, CDR2 or CDR3 amino acid sequences are set forth in Table 1 or SEQ ID NOs: 16-18, 22-24 and 28-30.~~

~~16. The antibody of any one of claims 10 to 15, comprising an amino acid sequence at least 70% identical to a light chain variable region amino acid sequence set forth in Table 1 or SEQ ID NOs: 4, 8 and 12.~~

~~17. The antibody of claim 16, comprising an amino acid sequence at least 85% identical to a light chain variable region amino acid sequence set forth in Table 1 or SEQ ID NOs: 4, 8 and 12.~~

~~18~~4. The antibody of claim 1 ~~16~~, comprising an amino acid sequence at least 95% identical to a light chain variable region amino acid sequence set forth in ~~Table 1 or~~ SEQ ID NOs: 4, 8 and 12.

~~19~~5. The antibody of claim ~~18~~4, comprising a light chain variable region amino acid sequence set forth in ~~Table 1 or~~ SEQ ID NOs: 4, 8 and 12.

~~20. The antibody of any one of claims 13 to 15 comprising a polypeptide sequence having an amino acid sequence at least 70% identical over all three LCDRs of a light chain variable region, the amino acid sequences of LCDR1, LCDR2 and LCDR3 set forth in SEQ ID NOs: 16-18, 22-24 and 28-30.~~

~~21. The antibody of any one of claims 13 to 15, comprising (i) an amino acid sequence at least 70% identical over all three LCDRs, of a light chain variable region, the amino acid sequences of LCDR1, LCDR2 and LCDR3 set forth in SEQ ID NOs: 16-18, 22-24 and 28-30 and (ii) an amino acid sequence at least 70% identical over all three HCDRs of a heavy chain variable region, the amino acid sequences of HCDR1, HCDR2 and HCDR3 set forth in SEQ ID NOs: 13-15, 19-21 and 25-27.~~

~~22~~6. An antibody that binds transforming growth factor beta (TGFβ)1, TGFβ2 and TGFβ3 comprising a light chain variable region and~~/or~~ a heavy chain variable region, wherein

(a) the light chain variable region comprises at least a CDR1 selected from SEQ ID NOs: 16, 22 and 28 ~~or sequences at least 80% identical thereto~~, a CDR2 selected from SEQ ID NOs: 17, 23 and 29 ~~or sequences at least 80% identical thereto~~, and~~/or~~ a CDR3 selected from SEQ ID NOs: 18, 24 and 30 ~~or sequences at least 80% identical thereto~~; and~~/or~~ wherein

(b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID NOs: 13, 19 and 25 ~~or sequences at least 80% identical thereto~~, a CDR2 selected from SEQ ID NOs: 14, 20 and 26 ~~or sequences at least 80% identical thereto~~, and~~/or~~ a CDR3 selected from SEQ ID NOs: 15, 21 and 27 ~~or sequences at least 80% identical thereto~~.

~~23. The antibody of claim 22, wherein~~

~~(a) the light chain variable region comprises at least a CDR1 selected from SEQ ID NO: 16 or sequences at least 90% identical thereto, a CDR2 selected from SEQ ID NO: 17 or sequences at least 90% identical thereto, and a CDR3 selected from SEQ ID NO: 18 or sequences at least 90% identical thereto; and/or wherein~~

~~(b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID NO: 13 or sequences at least 90% identical thereto, a CDR2 selected from SEQ ID NO: 14 or sequences at least 90% identical thereto, and a CDR3 selected from SEQ ID NO: 15 or sequences at least 90% identical thereto.~~

~~24. The antibody of claim 22, wherein~~

~~(a) the light chain variable region comprises at least a CDR1 selected from SEQ ID NO: 22 or sequences at least 90% identical thereto, a CDR2 selected from SEQ ID NO: 23 or sequences at least 90% identical thereto, and a CDR3 selected from SEQ ID NO: 24 or sequences at least 90% identical thereto; and/or wherein~~

~~(b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID NO: 19 or sequences at least 90% identical thereto, a CDR2 selected from SEQ ID NO: 20 or sequences at least 90% identical thereto, and a CDR3 selected from SEQ ID NO: 21 or sequences at least 90% identical thereto.~~

~~25. The antibody of claim 22, wherein~~

~~(a) the light chain variable region comprises at least a CDR1 selected from SEQ ID NO: 28 or sequences at least 90% identical thereto, a CDR2 selected from SEQ ID NO: 29 or sequences at least 90% identical thereto, and a CDR3 selected from SEQ ID NO: 30 or sequences at least 90% identical thereto; and/or wherein~~

~~(b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID NO: 25 or sequences at least 90% identical thereto, a CDR2 selected from SEQ ID NO: 26 or sequences at least 90% identical thereto, and a CDR3 selected from SEQ ID NO: 27 or sequences at least 90% identical thereto.~~

~~26~~7. The antibody of any one of claims 1 to ~~25~~6, further comprising a heavy chain constant region, wherein the heavy chain constant region is a modified or unmodified IgG, IgM, IgA, IgD, IgE, a fragment thereof, or combinations thereof.

~~278~~. The antibody of any one of claims ~~134~~ to ~~267~~, in which one or more light chain framework amino acids have been replaced with corresponding amino acid(s) from another human antibody amino acid sequence.

~~289~~. The antibody of any one of claims 1 ~~to 3, 13 to 14~~ or ~~226~~, wherein the antibody is selected from XPA.42.089 having a heavy chain variable region amino acid sequence set out in SEQ ID NO: 6 and a light chain variable region amino acid sequence set out in SEQ ID NO: 8, XPA.42.068 having a heavy chain variable region set forth in SEQ ID NO: 10 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 12 and XPA.42.681 having a heavy chain variable region amino acid sequence set out in SEQ ID NO: 10 and a light chain variable region amino acid sequence set out in SEQ ID NO: 4.

~~2910~~. The antibody of any of claims ~~134~~ to ~~289~~, further comprising a human light chain constant region attached to said light chain variable region.

~~3011~~. The antibody of claim ~~2910~~, wherein the light chain constant region is a modified or unmodified lambda light chain constant region, a kappa light chain constant region, a fragment thereof, or combinations thereof.

~~3112~~. An antibody of any one of the preceding claims that binds TGFβ1, TGFβ2 and TGFβ3 with an affinity Kd of 10^{-6} M or less.

~~3213~~. An antibody of any one of claims 1 to ~~3112~~, wherein the antibody binds to TGFβ1 and TGFβ2 with greater affinity than TGFβ3.

~~3314~~. An antibody of any one of claims 1 to ~~3213~~, wherein the antibody neutralizes activity of TGFβ1 and TGFβ2 to a greater extent than TGFβ3.

~~3415~~. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the heavy chain or light chain of any one of claims 1 to ~~3314~~.

~~3516~~. An expression vector comprising the nucleic acid molecule of claim ~~3415~~ operably linked to an expression control sequence.

~~3617~~. A host cell comprising the vector of claim ~~3516~~ or a nucleic acid molecule of claim ~~3415~~.

~~3718~~. The host cell of claim ~~3617~~, comprising a nucleic acid molecule encoding a heavy chain and a light chain variable region, wherein the heavy chain and light chain nucleic acids are expressed by different nucleic acids or on the same nucleic acid.

~~38~~19. A method of using the host cell of claim ~~36~~17 or ~~37~~18 to produce an antibody, comprising culturing the host cell of claim ~~36~~17 or ~~37~~18 under suitable conditions and recovering said antibody.

~~39~~20. An antibody produced by the method of claim ~~38~~19.

~~40~~21. A sterile pharmaceutical composition comprising the antibody of any one of claims 1-~~33~~14 and ~~39~~20 and a pharmaceutically acceptable carrier.

~~41~~22. Use of an antibody of any one of claims 1 to ~~33~~14 or a pharmaceutical composition of claim ~~40~~21 for the manufacture of a medicament for treating a disease, condition or disorder associated with TGFβ expression in a subject in need thereof.

~~42~~23. The use of claim ~~41~~22, wherein the disease, condition or disorder is selected from the group consisting of cancer, eye diseases, conditions or disorders, ophthalmic fibroses or fibrosis of the eye, pulmonary fibrosis, idiopathic pulmonary fibrosis, peribronchiolar fibrosis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), small airway disease (e.g., obstructive bronchiolitis), emphysema, adult or acute respiratory distress syndrome (ARDS), acute lung injury (ALI); pulmonary fibrosis due to infectious or toxic agents; kidney fibrosis, glomerulonephritis (GN) of all etiologies, mesangial proliferative GN, immune GN, and crescentic GN, glomerulosclerosis, tubulointerstitial injury, renal interstitial fibrosis, renal fibrosis and all causes of renal interstitial fibrosis, renal fibrosis resulting from complications of drug exposure, cyclosporin treatment of transplant recipients, HIV-associated nephropathy, transplant necropathy, diabetic kidney disease (diabetic nephropathy), nephrogenic systemic fibrosis, diabetes, idiopathic retroperitoneal fibrosis, scleroderma, liver fibrosis, hepatic diseases associated with excessive scarring and progressive sclerosis, liver cirrhosis, disorders of the biliary tree, hepatic dysfunction attributable to infections, fibrocystic diseases, cardiovascular diseases, congestive heart failure, dilated cardiomyopathy; myocarditis; vascular stenosis cardiac fibrosis (post-infarction cardiac fibrosis), post myocardial infarction, left ventricular hypertrophy, veno-occlusive disease, restenosis, post-angioplasty restenosis, arteriovenous graft failure, atherosclerosis, hypertension, hypertensive heart disease, cardiac hypertrophy, hypertrophic cardiomyopathy, heart failure, disease of the aorta, progressive systemic sclerosis, polymyositis, systemic lupus erythematosus, dermatomyositis, fascists, Raynaud's

syndrome, rheumatoid arthritis, , Peyronie's disease, systemic sclerosis, post-spinal cord injury, osteoporosis, Camurati-Engelmann disease, Crohn's disease, scarring, Marfan syndrome, premature ovarian failure, Alzheimer's Disease and Parkinson's Disease, fibrosis due to surgical incisions or mechanical trauma, fibrosis associated with ocular surgery; and excessive or hypertrophic scar or keloid formation in the dermis occurring during wound healing resulting from trauma or surgical wounds.

~~43~~24. The use of claim ~~42~~23, wherein the disease, condition or disorder is an eye disease, condition or disorder selected from the group consisting of fibroproliferative disorders, fibrosis of the eye, ophthalmic fibroses, retinal dysfunction, fibrosis associated with retinal dysfunction, wet or dry macular degeneration, proliferative vitreoretinopathy, vitreoretinopathy of any etiology, fibrosis associated with ocular surgery such as treatment of glaucoma, retinal reattachment, cataract extraction, or drainage procedures of any kind, scarring in the cornea and conjunctiva, fibrosis in the corneal endothelium, alkali burn (e.g., alkali burn to the cornea), post-cataract surgery fibrosis of the lens capsule, excess scarring in the tissue around the extraocular muscles in the strabismus surgery, anterior subcapsular cataract and posterior capsule opacification, anterior segment fibrotic diseases of the eye, fibrosis of the corneal stroma (e.g., associated with corneal opacification), fibrosis of the trabecular network (e.g., associated with glaucoma), posterior segment fibrotic diseases of the eye, fibrovascular scarring (e.g., in retinal or choroidal vasculature of the eye), retinal fibrosis, epiretinal fibrosis, retinal gliosis, subretinal fibrosis (e.g., associated with age related macular degeneration), fibrosis associated with post-retinal and glaucoma surgery, and tractional retinal detachment in association with contraction of the tissue in diabetic retinopathy.

~~44~~25. The use of claim ~~42~~23, wherein the disease, condition or disorder is a fibroproliferative eye disease, condition, or disorder, fibrosis of the eye, or ophthalmic fibrosis.

~~45~~26. Use of an antibody of any one of claims 1 to ~~33~~14 or a pharmaceutical composition of claim ~~40~~21 for the manufacture of a medicament for treating cancer in a subject in need thereof.

~~46~~27. The use of claim ~~45~~26, wherein the antibody or composition increases the number of natural killer (NK) cells in a tumor and/or improves NK cell cytolytic activity.

~~47~~28. The use of claim ~~45~~26, wherein the antibody or composition decreases the number of regulatory T cells in a tumor and/or inhibits regulatory T cell function.

~~48~~29. The use of claim ~~45~~26, wherein the antibody or composition increases the number of cytotoxic T cells (CTLs) in a tumor and/or enhances CTL function.

~~49~~30. The use of claim ~~45~~26, wherein the antibody decreases the number of myeloid-derived suppressor cells (MDSC) in a tumor and/or inhibits MDSC function.

~~50~~31. The use of claim 4426, wherein the antibody decreases the number of dendritic cells (DC) in a tumor and/or inhibits the tolerogenic function of dendritic cells.

~~51~~32. The use of any one of claims ~~45~~26 to ~~50~~31, wherein the cancer is selected from the group consisting of lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma.

~~52~~33. Use of an antibody of any one of claims 1 to ~~33~~14 or a pharmaceutical composition of claim ~~40~~21 for the manufacture of a medicament for treating fibrosis in a subject in need thereof.

~~53~~34. A composition comprising an antibody of any one of claims 1 to ~~33~~14 or a pharmaceutical composition of claim ~~40~~21 for use in treating a condition or disorder associated with TGFβ expression.

35. The antibody of claim 1 or 6 comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 8.

36. The antibody of claim 1 or 6, comprising a heavy chain variable region set forth in SEQ ID NO: 10 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 12.

37. The antibody of claim 1 or 6 comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 10 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 4.